Andreas Pahl

Company: Heidelberg Pharma Research

Job title: Chief Scientific Officer

Seminars:

Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy 3:45 pm

Discussing a new payload with a new mode of action providing new options to fight cancer Understanding how the ATAC platform optimized the ADC technology for that payload Reviewing HDP-101 targeting BCMA; the first ATAC which cleared IND and is now in dose escalation in myeloma patientsRead more

day: day 1- pm